MEDIA

Growing CLIA System Installations to Drive Reagent and Consumables Revenue, Supporting Long-Term Business Growth

Hsinchu, Taiwan — August 10, 2026

General Biologicals Corporation (GBC, hereinafter referred to as “GBC”; TWSE: 4117), a precision healthcare solutions provider, today announced consolidated revenue of NT$24.63 million for July 2026, representing a 57.82% year-on-year increase. The growth was primarily driven by continued growth in orders for its precision healthcare testing business. Some overseas reagent orders have been rescheduled by customers and will be recognized progressively from August. This adjustment does not affect overall order momentum or the Company’s full-year operating outlook. Consolidated revenue for January through July 2026 totaled NT$179.85 million, up 41.77% from the same period last year.

GBC stated that its CLIA Chemiluminescence Immunoassay System is expected to be one of the key growth drivers of its precision healthcare business. The CLIA platform has gradually been introduced into healthcare institutions and laboratories in Taiwan. Its business model leverages instrument placements to generate continued demand for reagents and consumables. Each additional system installed is expected to create long-term testing demand and recurring revenue opportunities. Currently, approximately 11 systems have been installed at healthcare institutions and laboratories in Taiwan. As the installed base continues to expand, the commercial benefits of the CLIA platform are expected to become increasingly evident.

GBC further stated that its CLIA Chemiluminescence Immunoassay System offers high efficiency, high throughput, and high sensitivity, supporting a wide range of testing applications, including tumor markers, thyroid function, hormones, and infectious diseases. More than 10 chemiluminescence reagent assays have obtained TFDA medical device approvals, while the Company continues to develop additional reagent products and pursue regulatory certifications.

As the medical testing market gradually shifts from individual testing toward automated and platform-based solutions and long-term health management, demand for automated testing systems, reagents, and consumables from healthcare institutions and laboratories is also increasing. This trend is expected to support GBC’s long-term growth through its “system placement + reagents and consumables” business model.

Looking ahead to the third quarter of 2026, GBC will focus on its development strategy of “proprietary instrument development + reagents and consumables + testing services + overseas regional distribution partnerships.” The Company will accelerate regulatory approvals and overseas market expansion for its CLIA Chemiluminescence Immunoassay System. In addition, continued sales growth from “oh care,” the proprietary brand of GBC’s subsidiary Gene Research Laboratories Co., Ltd. (GRL), is expected to contribute positively to future operating performance.

For the second half of 2026, GBC will continue to expand CLIA system installations, broaden its chemiluminescence reagent portfolio, increase utilization among existing healthcare institutions, and accelerate overseas market expansion. These efforts are expected to progressively enhance the commercial value of the CLIA platform and lay a solid foundation for future business growth.

In addition, continued growth in sales of “oh care,” together with ongoing development in AI-assisted interpretation, digital pathology, and precision healthcare solutions, will enable GBC to further strengthen its integrated precision healthcare offerings and long-term competitive advantages, supporting sustainable business growth.

GBC Consolidated Revenue Summary for July 2026

Unit: NT$ thousand; %

Period	2026	2025	YoY %
July	24,625	15,603	57.82
January–July	179,845	126,856	41.77

Media Contacts

General Biologicals Corporation (GBC)
M. D. Lin, General Manager
Tel: +886-3-577-9221
frank.lin@gbc.com.tw

IR Trust
Sandy Cheng, Vice President
Tel: +886-2-2585-5701 / +886-931-914-467
sandy@ir-trust.tw

About GBC

General Biologicals Corporation (GBC; TWSE: 4117) was founded in June 1984 and has established an integrated value chain covering research, development, manufacturing, sales, and testing services. For more than 40 years, GBC has remained committed to its goal of creating better and more affordable in-vitro diagnostic (IVD) products that are accessible to everyone.

Its product portfolio covers infectious diseases, respiratory infections, blood virology, fertility and sexual health, oncology, human genetics, and emerging infectious diseases. GBC’s IVD products and instruments have become trusted solutions for healthcare professionals, laboratory technicians, blood banks, and consumers worldwide, with products currently sold in more than 40 countries.

Building on its expertise in testing, GBC is committed to integrating testing with other healthcare approaches and expanding into precision healthcare, preventive healthcare, and broader health management. Its business areas include precision IVD reagents, Digital Medical Laboratory (DML) services, antimicrobial peptide (AMP) pharmaceuticals, and healthcare product commercialization. Through a diversified business model, GBC is building a long-term presence in the broader healthcare sector.

GBC Official Website: https://www.gbc.com.tw/tw/home/

Disclaimer

This document and the related information released concurrently contain forward-looking statements. Except for statements relating to facts that have already occurred, all statements concerning GBC’s future business operations, potential events, and prospects, including but not limited to forecasts, targets, estimates, and operating plans, constitute forward-looking statements.

Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ materially from those expressed or implied herein. These factors include, but are not limited to, price fluctuations, actual demand, exchange-rate movements, market share, market competition, changes in legal, financial, and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the Company’s control.

These forward-looking statements are based on current expectations and assessments. The Company assumes no obligation to update or revise such statements in the future.